Article Text

Download PDFPDF
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial
  1. A. N. Fiander*,
  2. A. J. Tristram*,
  3. E. J. Davidson,,
  4. A. E. Tomlinson§,
  5. S. Man,
  6. P. J. Baldwin,
  7. J. C. Sterling# and
  8. H. C. Kitchener
  1. * Academic Department of Obstetrics and Gynaecology, Wales College of Medicine, Cardiff University, Cardiff, United Kingdom
  2. Academic Unit of Obstetrics and Gynaecology, University of Manchester, Manchester, United Kingdom
  3. Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
  4. § Colposcopy Unit, St Mary's Hospital NHS Trust, Manchester, United Kingdom
  5. Section of Immunology, Department of Pathology, Wales College of Medicine, Cardiff University, Cardiff, United Kingdom
  6. Department of Gynaecological Oncology, Cambridge, United Kingdom
  7. # Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, United Kingdom
  1. Address correspondence and reprint requests to: Prof. Alison N Fiander, MSc, FRCOG, DM, Academic Department of Obstetrics and Gynaecology, Wales College of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. Email: fianderan{at}


The objective of this study was to determine the clinical effectiveness of a prime-boost human papillomavirus (HPV) vaccine regimen. A nonrandomized phase II prime-boost vaccine trial was conducted. Women with biopsy-proven anogenital intraepithelial neoplasia (AGIN) 3 were vaccinated with three doses of a recombinant fusion protein comprising HPV 16, E6/E7/L2 (TA-CIN) followed by one dose of a recombinant vaccinia virus encoding HPV 16 and 18 E6/E7 (TA-HPV). Clinical responses were evaluated by serial photographs, symptomatology, and biopsies before and after vaccination. Twenty-nine women were vaccinated; 27 with vulval intraepithelial neoplasia 3 and 2 with vaginal intraepithelial neoplasia grade 3. Clinical responses were seen in five women (17%), with one complete and five partial responses. Fifteen women (62%) had symptomatic improvement. No serious adverse effects were recorded. This is the first trial of a prime-boost vaccination regimen using heterologous HPV vaccines (TA-CIN followed by TA-HPV) in the management of AGIN. Since the prime-boost approach in this cohort offered no significant advantages over single TA-HPV vaccination, there are no further studies planned using this protocol. Future studies are warranted to define responders to immunotherapy.

  • anogenital neoplasia
  • human papillomavirus
  • intraepithelial neoplasia
  • therapeutic vaccines
  • vulval intraepithelial neoplasia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.